Unlock the Power of an Aventria Executive ThinkTank™ to Prepare for the IRA
Pharmaceutical SVP/VP Market Access, SVP Therapeutic Business Units, Brand Directors, SVP/VP Policy/Government Affairs, US-Executive Committee Members:
The Inflation Reduction Act (IRA) will create unprecedented changes, and no one can accurately predict exactly how it all will play out for pharma manufacturers and the healthcare system at large. Most pharma organizations have modeled the potential impact on revenue but not the downstream consequences to:
New customer business models
Drug access/coverage requirements
Launch list price strategies
Overall patient care
Is your organization fully prepared to anticipate and address some of the profound regulation and pricing changes coming? Are you considering the following:
Pharma and payer uncertainties on revenue protection and generation
Impact on list price and discounts/rebates, launch pricing, price increases above CPI, benefit design, patient out-of-pocket caps, reimbursement support programs, drug fulfillment, and payer negotiation windows
Early commercialization impact on R&D strategy, priority therapeutic areas, degree of innovation, and commercial viability of markets
Indirect consequences such as heightened payer concern for specialty/rare-disease therapies that will impact launch price and potential label expansions to larger patient populations
In short, are you ready for the disruption in your ability to do business as usual?
2023/2024 is the transition year for you to fully understand the IRA’s impact and proactively create brand strategies.
Retrospective analysis and previous research do not provide the answers to new questions posed by IRA. It is important for Pharma to utilize innovative processes and strategic planning tools better suited for complex environments. The processes and tools should stimulate the best thinking and dialogues so you can find the clarity needed to anticipate and plan for success in a unified manner.
Aventria Health Group can help Market Access Leadership Teams and others leverage their position within the organization to create a strong, integrated planning process for responding to the IRA changes and other key dynamics.
The Aventria Executive ThinkTank™
The dynamic Aventria Executive ThinkTank (live or virtual) dives deep into the intricate realm of IRA to better comprehend its dynamics (eg, trends, stakeholder needs, market shifts, evolving payer business models) and what they could mean for future pharma business models, memorable customer engagement, and patient outcomes.
We bring together influential leaders in healthcare to create an inspiring and groundbreaking workshop.
Participants represent a cross section of payer, provider, and policy leaders, and high-ranking pharma personnel. The ThinkTank is designed to create:
Robust dialogue between participants, leading to strategic insights, new business assumptions, and opportunities for collaboration that enhance efficient, cost-effective, and quality patient care
A common backdrop borne from understanding the concerns of different functional groups and aligning on common terminology and ways of articulating issues
Collaborative approaches and aligned strategies between senior leaders that develop unified solutions, economic and resource efficiencies, and a winning brand/development pipeline path forward
Our Aventria Executive ThinkTank provides you with cutting-edge methodology that will get your leadership team perfectly in sync and galvanize the best thinking to anticipate IRA impact and prepare for future success.
To learn more about the Aventria Executive ThinkTank process and how we can help you anticipate the unprecedented impact of the IRA and prepare for future success, please reach out to:
Dave Dierk, Co-President, 30-year sales and marketing thought leader in pharmaceutical diagnostics, biomedical, long-term care, managed care, employer, and pharmacy communications, at firstname.lastname@example.org.
Paul G. Pochtar, RPh, extensive experience in leading the successful market access commercialization of both primary care and specialty pharmaceuticals throughout their life cycle, including several landmark oncology products and other specialty therapeutics, at email@example.com.
Making a difference in patient care by helping patients, providers, and payers collaborate on shared priorities